OTLK
Outlook Therapeutics, Inc.$1.22+0.12 (+10.45%)Prev Close$1.10·MCap$11.7M·P/E—·Vol35.21M·Yield—
▲
Buys (12M)
6
$5.27M
▼
Sells (12M)
0
$0.00
◆
Net Activity
Net Buyer
$5.27M
●
Active Insiders
5
last 12 mo
Over the past 12 months, insider activity at Outlook Therapeutics, Inc. (OTLK) has been exclusively buying, with 6 insider purchases totaling $5.27M and 0 insider sales totaling $0.00. The most recent insider transaction was by Haddadin Yezan Munther (director), who purchased $24.1K worth of shares on Jun 3, 2026. Outlook Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $11.7M.
OTLK Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 3, 2026 | Haddadin Yezan Munther | director | Buy | 29,000 | $0.83 | $24.1K | 66,167+78% |
| Jun 1, 2026 | Sukhtian Ghiath M. | director, 10 percent owner: | Buy | 8,539,709 | $0.59 | $5.00M20.8% OS | 22,092,068+63% |
| May 27, 2026 | Sukhtian Faisal Ghiath | director | Buy | 122,174 | $0.41 | $50.0K | 125,574New Position |
| May 27, 2026 | THURMAN RANDY H | director | Buy | 5,000 | $0.43 | $2.1K | 5,593+843% |
| May 27, 2026 | HILZINGER KURT J | director | Buy | 400,000 | $0.44 | $176.5K1.0% OS | 423,655New Position |
| May 27, 2026 | Haddadin Yezan Munther | director | Buy | 34,000 | $0.44 | $15.0K | 37,167New Position |
| Sep 30, 2024 | KENYON LAWRENCE A | Chief Financial Officer | Buy | 5,000 | $5.69 | $28.4K | 5,946+529% |
| Mar 29, 2024 | Haddadin Yezan Munther | Buy | 1,881 | $11.82 | $22.2K | 5,049+59% | |
| Mar 11, 2024 | Evanson Jeff | CHIEF COMMERCIAL OFFICER | Buy | 62,484 | $0.42 | $26.2K | 808,459 |
| Apr 21, 2023 | Dagnon Terry | Chief Operations Officer | Sell | 520,000 | $1.14 | $590.2K1.3% OS | 653,058-44% |
| Jan 24, 2023 | Evanson Jeff | Chief Commercial Officer | Sell | 267,000 | $1.11 | $296.4K0.6% OS | 745,975-26% |
| Jan 19, 2023 | Evanson Jeff | Chief Commercial Officer | Sell | 164,155 | $1.24 | $203.7K | 1,149,968 |
| Oct 11, 2022 | Haddadin Yezan Munther | Director | Buy | 33,343 | $1.29 | $42.9K | 63,343+111% |
| Oct 11, 2022 | Sukhtian Faisal Ghiath | Director | Buy | 30,000 | $1.29 | $38.7K | 68,000+79% |
| Oct 5, 2022 | HILZINGER KURT J | Director | Buy | 111,203 | $1.28 | $142.5K | 473,117+31% |
| Oct 3, 2022 | HILZINGER KURT J | Director | Buy | 88,797 | $1.24 | $110.5K | 361,914+33% |
| Jun 23, 2022 | Dagnon Terry | Chief Operating Officer | Buy | 10,000 | $1.05 | $10.5K | 1,173,058 |
| Jun 23, 2022 | TRENARY C RUSSELL III | CEO and President | Buy | 19,925 | $1.06 | $21.1K | 54,925+57% |
| Mar 3, 2022 | HILZINGER KURT J | Director | Buy | 27,708 | $1.69 | $46.8K | 273,117 |
| Feb 28, 2022 | HILZINGER KURT J | Director | Buy | 47,160 | $1.48 | $69.7K | 245,409 |
| Feb 23, 2022 | HILZINGER KURT J | Director | Buy | 175,132 | $1.47 | $257.0K | 198,249+758% |
| Dec 6, 2021 | Dagnon Terry | Chief Operating Officer | Buy | 25,201 | $1.38 | $34.8K | 1,163,058 |
| Dec 6, 2021 | Evanson Jeff | Chief Commercial Officer | Buy | 35,200 | $1.34 | $47.2K | 1,177,130 |
| Dec 6, 2021 | TRENARY C RUSSELL III | CEO and President | Buy | 25,000 | $1.39 | $34.8K | 35,000+250% |
| Dec 3, 2021 | Dagnon Terry | Chief Operating Officer | Buy | 10,000 | $1.42 | $14.2K | 1,137,857 |
| Dec 2, 2021 | Haddadin Yezan Munther | Director | Buy | 10,000 | $1.39 | $13.9K | 30,000+50% |
| Dec 2, 2021 | Sukhtian Faisal Ghiath | Director | Buy | 18,000 | $1.40 | $25.2K | 38,000+90% |
| Dec 2, 2021 | TRENARY C RUSSELL III | CEO and President | Buy | 10,000 | $1.40 | $14.0K | 10,000 |
| Dec 1, 2021 | Sukhtian Ghiath M. | Director | Buy | 16,000,000 | $1.25 | $20.00M38.9% OS | 27,834,256+135% |
| Apr 20, 2021 | Haddadin Yezan Munther | Director | Buy | 10,000 | $1.82 | $18.2K | 20,000+100% |
| Apr 20, 2021 | KENYON LAWRENCE A | CEO, Pres, CFO, Treas & Secy | Buy | 10,000 | $1.83 | $18.3K | 18,926+112% |
OTLK Insider Buying Activity
The following table shows recent insider purchases of Outlook Therapeutics, Inc. (OTLK) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 3, 2026 | Haddadin Yezan Munther | director | Buy | 29,000 | $0.83 | $24.1K | 66,167+78% |
| Jun 1, 2026 | Sukhtian Ghiath M. | director, 10 percent owner: | Buy | 8,539,709 | $0.59 | $5.00M20.8% OS | 22,092,068+63% |
| May 27, 2026 | Sukhtian Faisal Ghiath | director | Buy | 122,174 | $0.41 | $50.0K | 125,574New Position |
| May 27, 2026 | THURMAN RANDY H | director | Buy | 5,000 | $0.43 | $2.1K | 5,593+843% |
| May 27, 2026 | HILZINGER KURT J | director | Buy | 400,000 | $0.44 | $176.5K1.0% OS | 423,655New Position |
| May 27, 2026 | Haddadin Yezan Munther | director | Buy | 34,000 | $0.44 | $15.0K | 37,167New Position |
| Sep 30, 2024 | KENYON LAWRENCE A | Chief Financial Officer | Buy | 5,000 | $5.69 | $28.4K | 5,946+529% |
| Mar 29, 2024 | Haddadin Yezan Munther | Buy | 1,881 | $11.82 | $22.2K | 5,049+59% | |
| Mar 11, 2024 | Evanson Jeff | CHIEF COMMERCIAL OFFICER | Buy | 62,484 | $0.42 | $26.2K | 808,459 |
| Oct 11, 2022 | Haddadin Yezan Munther | Director | Buy | 33,343 | $1.29 | $42.9K | 63,343+111% |
| Oct 11, 2022 | Sukhtian Faisal Ghiath | Director | Buy | 30,000 | $1.29 | $38.7K | 68,000+79% |
| Oct 5, 2022 | HILZINGER KURT J | Director | Buy | 111,203 | $1.28 | $142.5K | 473,117+31% |
| Oct 3, 2022 | HILZINGER KURT J | Director | Buy | 88,797 | $1.24 | $110.5K | 361,914+33% |
| Jun 23, 2022 | Dagnon Terry | Chief Operating Officer | Buy | 10,000 | $1.05 | $10.5K | 1,173,058 |
| Jun 23, 2022 | TRENARY C RUSSELL III | CEO and President | Buy | 19,925 | $1.06 | $21.1K | 54,925+57% |
| Mar 3, 2022 | HILZINGER KURT J | Director | Buy | 27,708 | $1.69 | $46.8K | 273,117 |
| Feb 28, 2022 | HILZINGER KURT J | Director | Buy | 47,160 | $1.48 | $69.7K | 245,409 |
| Feb 23, 2022 | HILZINGER KURT J | Director | Buy | 175,132 | $1.47 | $257.0K | 198,249+758% |
| Dec 6, 2021 | Dagnon Terry | Chief Operating Officer | Buy | 25,201 | $1.38 | $34.8K | 1,163,058 |
| Dec 6, 2021 | Evanson Jeff | Chief Commercial Officer | Buy | 35,200 | $1.34 | $47.2K | 1,177,130 |
| Dec 6, 2021 | TRENARY C RUSSELL III | CEO and President | Buy | 25,000 | $1.39 | $34.8K | 35,000+250% |
| Dec 3, 2021 | Dagnon Terry | Chief Operating Officer | Buy | 10,000 | $1.42 | $14.2K | 1,137,857 |
| Dec 2, 2021 | Haddadin Yezan Munther | Director | Buy | 10,000 | $1.39 | $13.9K | 30,000+50% |
| Dec 2, 2021 | Sukhtian Faisal Ghiath | Director | Buy | 18,000 | $1.40 | $25.2K | 38,000+90% |
| Dec 2, 2021 | TRENARY C RUSSELL III | CEO and President | Buy | 10,000 | $1.40 | $14.0K | 10,000 |
| Dec 1, 2021 | Sukhtian Ghiath M. | Director | Buy | 16,000,000 | $1.25 | $20.00M38.9% OS | 27,834,256+135% |
| Apr 20, 2021 | Haddadin Yezan Munther | Director | Buy | 10,000 | $1.82 | $18.2K | 20,000+100% |
| Apr 20, 2021 | KENYON LAWRENCE A | CEO, Pres, CFO, Treas & Secy | Buy | 10,000 | $1.83 | $18.3K | 18,926+112% |
OTLK Insider Selling Activity
The following table shows recent insider sales of Outlook Therapeutics, Inc. (OTLK) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Apr 21, 2023 | Dagnon Terry | Chief Operations Officer | Sell | 520,000 | $1.14 | $590.2K1.3% OS | 653,058-44% |
| Jan 24, 2023 | Evanson Jeff | Chief Commercial Officer | Sell | 267,000 | $1.11 | $296.4K0.6% OS | 745,975-26% |
| Jan 19, 2023 | Evanson Jeff | Chief Commercial Officer | Sell | 164,155 | $1.24 | $203.7K | 1,149,968 |
OTLK Insiders
Similar Stocks to OTLK
VRTX
Vertex Pharmaceuticals Incorporated
$445.21+0.04%
$113.41B
REGN
Regeneron Pharmaceuticals, Inc.
$614.20+0.45%
$65.47B
ALNY
Alnylam Pharmaceuticals, Inc.
$283.35-2.09%
$40.46B
RVMD
Revolution Medicines, Inc.
$153.65+2.96%
$31.73B
UTHR
United Therapeutics Corporation
$542.43-0.54%
$23.12B
INSM
Insmed Incorporated
$98.28+1.64%
$20.41B
INCY
Incyte Corporation
$108.85+0.95%
$20.11B
MRNA
Moderna, Inc.
$50.18+1.06%
$18.89B